StockData
Annovis Bio, Inc. logo

Annovis Bio, Inc. (ANVS) stock

ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.74−0.01 (-0.91%)

Close on Nov 17, 2026Market cap $31.66MP/E –Yield –

Annovis Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Annovis Bio's operating income for the twelve months ending Jun 30, 2026 was -$49.53M. For fiscal 2025 it was -$29.70M. The highest annual figure on record is -$1.61M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.70M–
FY2024Dec 31, 2024-$26.69M–
FY2023Dec 31, 2023-$45.04M–
FY2022Dec 31, 2022-$25.51M–
FY2021Dec 31, 2021-$14.54M–
FY2020Dec 31, 2020-$6.64M–
FY2019Dec 31, 2019-$1.61M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.38M–
Q1 FY2026Mar 31, 2026-$18.01M–
Q4 FY2025Dec 31, 2025-$9.71M–
Q3 FY2025Sep 30, 2025-$7.43M–
Q2 FY2025Jun 30, 2025-$6.27M–
Q1 FY2025Mar 31, 2025-$6.28M–
Q4 FY2024Dec 31, 2024-$6.73M–
Q3 FY2024Sep 30, 2024-$4.39M–
Q2 FY2024Jun 30, 2024-$7.76M–
Q1 FY2024Mar 31, 2024-$7.81M–
Q4 FY2023Dec 31, 2023-$10.44M–
Q3 FY2023Sep 30, 2023-$14.86M–
Q2 FY2023Jun 30, 2023-$9.76M–
Q1 FY2023Mar 31, 2023-$9.97M–
Q4 FY2022Dec 31, 2022-$7.80M–
Q3 FY2022Sep 30, 2022-$6.48M–
Q2 FY2022Jun 30, 2022-$5.97M–
Q1 FY2022Mar 31, 2022-$5.25M–
Q4 FY2021Dec 31, 2021-$5.92M–
Q3 FY2021Sep 30, 2021-$2.85M–
Q2 FY2021Jun 30, 2021-$2.53M–
Q1 FY2021Mar 31, 2021-$3.23M–
Q4 FY2020Dec 31, 2020-$1.91M–
Q3 FY2020Sep 30, 2020-$1.60M–
Q2 FY2020Jun 30, 2020-$2.54M–
Q1 FY2020Mar 31, 2020-$583.16K–
Q4 FY2019Dec 31, 2019-$870.96K–
Q3 FY2019Sep 30, 2019-$241.79K–
Q2 FY2019Jun 30, 2019-$306.08K–
Q1 FY2019Mar 31, 2019-$186.79K–

More Annovis Bio figures

See a number that looks wrong?